BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

653 related articles for article (PubMed ID: 26560119)

  • 1. E3 Ubiquitin Ligases as Molecular Targets in Human Oral Cancers.
    Masumoto K; Kitagawa M
    Curr Cancer Drug Targets; 2016; 16(2):130-5. PubMed ID: 26560119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The SCF-type E3 Ubiquitin Ligases as Cancer Targets.
    Kitagawa K; Kitagawa M
    Curr Cancer Drug Targets; 2016; 16(2):119-29. PubMed ID: 26560120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p27(Kip1) signaling: Transcriptional and post-translational regulation.
    Hnit SS; Xie C; Yao M; Holst J; Bensoussan A; De Souza P; Li Z; Dong Q
    Int J Biochem Cell Biol; 2015 Nov; 68():9-14. PubMed ID: 26279144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of SCF-Skp2/Cks1 E3 ligase block estrogen-induced growth stimulation and degradation of nuclear p27kip1: therapeutic potential for endometrial cancer.
    Pavlides SC; Huang KT; Reid DA; Wu L; Blank SV; Mittal K; Guo L; Rothenberg E; Rueda B; Cardozo T; Gold LI
    Endocrinology; 2013 Nov; 154(11):4030-45. PubMed ID: 24035998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-throughput screening AlphaScreen assay for identification of small-molecule inhibitors of ubiquitin E3 ligase SCFSkp2-Cks1.
    Ungermannova D; Lee J; Zhang G; Dallmann HG; McHenry CS; Liu X
    J Biomol Screen; 2013 Sep; 18(8):910-20. PubMed ID: 23589337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen and progesterone regulate p27kip1 levels via the ubiquitin-proteasome system: pathogenic and therapeutic implications for endometrial cancer.
    Huang KT; Pavlides SC; Lecanda J; Blank SV; Mittal KR; Gold LI
    PLoS One; 2012; 7(9):e46072. PubMed ID: 23029392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PTEN regulates the ubiquitin-dependent degradation of the CDK inhibitor p27(KIP1) through the ubiquitin E3 ligase SCF(SKP2).
    Mamillapalli R; Gavrilova N; Mihaylova VT; Tsvetkov LM; Wu H; Zhang H; Sun H
    Curr Biol; 2001 Feb; 11(4):263-7. PubMed ID: 11250155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. E3 ubiquitin ligases as drug targets and prognostic biomarkers in melanoma.
    Bielskienė K; Bagdonienė L; Mozūraitienė J; Kazbarienė B; Janulionis E
    Medicina (Kaunas); 2015; 51(1):1-9. PubMed ID: 25744769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RING-, HECT-, and RBR-type E3 Ubiquitin Ligases: Involvement in Human Cancer.
    Uchida C; Kitagawa M
    Curr Cancer Drug Targets; 2016; 16(2):157-74. PubMed ID: 26560116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of E3 ubiquitin ligases in gastric cancer.
    Hou YC; Deng JY
    World J Gastroenterol; 2015 Jan; 21(3):786-93. PubMed ID: 25624711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of Skp2 and its substrate CDKN1B (p27) in colorectal cancer.
    Bochis OV; Irimie A; Pichler M; Berindan-Neagoe I
    J Gastrointestin Liver Dis; 2015 Jun; 24(2):225-34. PubMed ID: 26114183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytoplasmic ubiquitin ligase KPC regulates proteolysis of p27(Kip1) at G1 phase.
    Kamura T; Hara T; Matsumoto M; Ishida N; Okumura F; Hatakeyama S; Yoshida M; Nakayama K; Nakayama KI
    Nat Cell Biol; 2004 Dec; 6(12):1229-35. PubMed ID: 15531880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of p27 by ubiquitin ligases and its pathological significance in human lung carcinomas.
    Dobashi Y; Tsubochi H; Minegishi K; Kitagawa M; Otani S; Ooi A
    Hum Pathol; 2017 Aug; 66():67-78. PubMed ID: 28601655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Damage-specific DNA binding protein 1 (DDB1) is involved in ubiquitin-mediated proteolysis of p27Kip1 in response to UV irradiation.
    Iovine B; Iannella ML; Bevilacqua MA
    Biochimie; 2011 May; 93(5):867-75. PubMed ID: 21237244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy.
    Chen Q; Xie W; Kuhn DJ; Voorhees PM; Lopez-Girona A; Mendy D; Corral LG; Krenitsky VP; Xu W; Moutouh-de Parseval L; Webb DR; Mercurio F; Nakayama KI; Nakayama K; Orlowski RZ
    Blood; 2008 May; 111(9):4690-9. PubMed ID: 18305219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pirh2 promotes ubiquitin-dependent degradation of the cyclin-dependent kinase inhibitor p27Kip1.
    Hattori T; Isobe T; Abe K; Kikuchi H; Kitagawa K; Oda T; Uchida C; Kitagawa M
    Cancer Res; 2007 Nov; 67(22):10789-95. PubMed ID: 18006823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Editorial: Ubiquitin E3 Ligases as Molecular Targets or Tools for Advanced Cancer Therapy.
    Kitagawa M
    Curr Cancer Drug Targets; 2016; 16(2):100. PubMed ID: 26791134
    [No Abstract]   [Full Text] [Related]  

  • 18. Skp1: Implications in cancer and SCF-oriented anti-cancer drug discovery.
    Hussain M; Lu Y; Liu YQ; Su K; Zhang J; Liu J; Zhou GB
    Pharmacol Res; 2016 Sep; 111():34-42. PubMed ID: 27238229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific small molecule inhibitors of Skp2-mediated p27 degradation.
    Wu L; Grigoryan AV; Li Y; Hao B; Pagano M; Cardozo TJ
    Chem Biol; 2012 Dec; 19(12):1515-24. PubMed ID: 23261596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of two distinct ubiquitin E3 ligase systems for p27 degradation in corneal endothelial cells.
    Lee JG; Kay EP
    Invest Ophthalmol Vis Sci; 2008 Jan; 49(1):189-96. PubMed ID: 18172092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.